Authority consultation for Spostare Therapeutics – Part 1

The fictitious company Spostare Therapeutics is developing savaxopride, a novel serotonin type 4 (5-HT4) receptor agonist for the treatment of gastroparesis (incomplete emptying of the stomach) and gastroesophageal reflux disease (GERD).